McKesson (MCK) Stock Forecast & Price Target

$719.07 -7.33 (-1.01%)

As of 05/20/2025 03:58 PM Eastern

McKesson - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 15 Analyst Ratings

Sell
0

Hold
3

Buy
12

Based on 15 Wall Street analysts who have issued ratings for McKesson in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 3 have given a hold rating, 11 have given a buy rating, and 1 has given a strong buy rating for MCK.

Consensus Price Target

$686.69
-4.50% Downside

According to the 15 analysts' twelve-month price targets for McKesson, the average price target is $686.69. The highest price target for MCK is $805.00, while the lowest price target for MCK is $579.00. The average price target represents a forecasted downside of -4.50% from the current price of $719.07.

Get the Latest News and Ratings for MCK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for McKesson and its competitors.

MCK Analyst Ratings Over Time

Type	Current Forecast 5/21/24 to 5/21/25	1 Month Ago 4/21/24 to 4/21/25	3 Months Ago 2/21/24 to 2/20/25	1 Year Ago 5/22/23 to 5/21/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	12 Buy rating(s)	13 Buy rating(s)	13 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$686.69	$668.50	$645.79	$571.47
Forecasted Upside	-4.50% Downside	-2.10% Downside	6.97% Upside	3.46% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

MCK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MCK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

McKesson Stock vs. The Competition

Type	McKesson	Medical Companies	S&P 500
Consensus Rating Score	2.87	2.81	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	-4.50% Downside	4,843.17% Upside	13.03% Upside
News Sentiment Rating	Very Positive News See Recent MCK News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
5/9/2025	Bank of America 4 of 5 stars	Michael Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$755.00 ➝ $800.00	+15.11%
4/29/2025	UBS Group 3 of 5 stars	Kevin Caliendo Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$708.00 ➝ $805.00	+14.56%
4/4/2025	Cfra Research 0 of 5 stars	A. Sundaram Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
4/3/2025	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Valiquette Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$630.00 ➝ $690.00	-3.81%
4/2/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Erin Wright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$642.00 ➝ $745.00	+9.18%
3/14/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Stephen Baxter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$641.00 ➝ $691.00	+7.31%
2/6/2025	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Elizabeth Anderson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$650.00 ➝ $675.00	+14.97%
1/10/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Daniel Grosslight Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$713.00 ➝ $677.00	+15.15%
11/7/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Coldwell Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
11/7/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Outperform	$531.00 ➝ $688.00	+25.25%
Get the Latest News and Ratings for MCK and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for McKesson and its competitors with MarketBeat's FREE daily newsletter.
10/7/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$665.00 ➝ $630.00	+29.78%
9/25/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$623.00 ➝ $579.00	+20.99%
8/21/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$656.00 ➝ $661.00	+19.54%
8/8/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$596.00 ➝ $616.00	+12.78%
6/24/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$570.00 ➝ $670.00	+11.10%
5/8/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$563.00 ➝ $652.00	+19.74%
2/26/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
8/11/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$450.00 ➝ $485.00	+11.71%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 01:46 AM ET.

Should I Buy McKesson Stock? MCK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, May 16, 2025. Please send any questions or comments about these McKesson pros and cons to contact@marketbeat.com.

McKesson
Bull Case

Here are some ways that investors could benefit from investing in McKesson Co.:

The current stock price is around $723, reflecting a strong performance in the market and indicating investor confidence.
Recent earnings reports show that McKesson Co. exceeded earnings expectations, reporting $10.12 per share, which is a significant increase from the previous year.
Analysts have a consensus rating of "Moderate Buy" for McKesson Co., with multiple firms raising their target prices, suggesting positive future growth potential.
The company has a solid revenue growth of 18.9% compared to the same quarter last year, indicating strong operational performance.
McKesson Co. has a low dividend payout ratio of approximately 11%, allowing for reinvestment in growth opportunities while still providing returns to shareholders.

McKesson
Bear Case

Investors should be bearish about investing in McKesson Co. for these reasons:

Despite strong earnings, McKesson Co. reported revenue that fell short of analyst estimates, which could raise concerns about future sales performance.
The company has a negative return on equity, which indicates that it is not generating profit effectively from its equity base.
Market volatility could impact McKesson Co.'s stock price, as evidenced by fluctuations in trading volume and price movements.
Some analysts have downgraded their ratings, indicating mixed sentiments about the stock's future performance.
The healthcare sector can be subject to regulatory changes, which may pose risks to McKesson Co.'s business operations and profitability.

MCK Forecast - Frequently Asked Questions

: According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for McKesson is $686.69, with a high forecast of $805.00 and a low forecast of $579.00.
: 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for McKesson in the last year. There are currently 3 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MCK shares.
: According to analysts, McKesson's stock has a predicted downside of -4.50% based on their 12-month stock forecasts.
: Over the previous 90 days, McKesson's stock had 1 downgrade by analysts.
: McKesson has been rated by research analysts at Bank of America, Cfra Research, Mizuho, Morgan Stanley, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like McKesson more than other "medical" companies. The consensus rating score for McKesson is 2.87 while the average consensus rating score for "medical" companies is 2.81. Learn more on how MCK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:MCK) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

McKesson (MCK) Stock Forecast & Price Target